Table 1.
Demographic and clinical characteristics of participants at baseline*
| Characteristic | Tirzepatide 5/10/15 mg (N=1896) |
Placebo (N=643) |
Overall (N=2539) |
| Age, years | 45.0±12.4 | 44.4±12.5 | 44.9±12.5 |
| Female sex, n (%) | 1278 (67.4) | 436 (67.8) | 1714 (67.5) |
| Race or ethnic group, n (%)† | |||
| American Indian or Alaska Native | 173 (9.1) | 58 (9.0) | 231 (9.1) |
| Asian | 205 (10.8) | 71 (11.0) | 276 (10.9) |
| Black or African American | 146 (7.7) | 55 (8.6) | 201 (7.9) |
| White | 1342 (70.8) | 450 (70.0) | 1792 (70.6) |
| Other | 30 (1.6) | 9 (1.4) | 39 (1.5) |
| Hispanic or Latino, n (%) | 904 (47.7) | 310 (48.2) | 1214 (47.8) |
| Duration of obesity, years | 14.5±10.9 | 14.0±10.7 | 14.4±10.8 |
| Body weight, kg | 104.8±22.4 | 104.8±21.4 | 104.8±22.1 |
| BMI, kg/m2 | 37.9±6.8 | 38.2±6.9 | 38.0±6.8 |
| BMI category, n (%) | |||
| <30 | 116 (6.1) | 24 (3.7) | 140 (5.5) |
| ≥30 to <35 | 649 (34.2) | 227 (35.3) | 876 (34.5) |
| ≥35 to <40 | 540 (28.5) | 180 (28.0) | 720 (28.4) |
| ≥40 | 591 (31.2) | 212 (33.0) | 803 (31.6) |
| Blood pressure, mm Hg | |||
| Systolic | 123.5±12.7 | 122.9±12.8 | 123.3±12.7 |
| Diastolic | 79.5±8.2 | 79.6±8.0 | 79.5±8.2 |
| Pulse, beats per minute | 72.2±9.7 | 72.9±9.3 | 72.4±9.6 |
| Lipid levels, mg/dL‡ | |||
| Total cholesterol | 188.4 (20.3) | 187.5 (20.6) | 188.2 (20.4) |
| HDL cholesterol | 47.6 (26.1) | 46.6 (27.0) | 47.3 (26.3) |
| LDL cholesterol | 110.1 (30.1) | 109.4 (30.7) | 109.9 (30.2) |
| Triglycerides | 127.5 (50.0) | 130.8 (49.2) | 128.3 (49.8) |
| eGFR, mL/min/1.73 m2¶ | 98.0±17.9 | 98.1±18.3 | 98.1±18.0 |
| Pre-diabetes, n (%) | 762 (40.2) | 270 (42.0) | 1032 (40.6) |
| Hypertension, n (%)§ | 620 (32.7) | 199 (30.9) | 819 (32.3) |
| Use of antihypertensive medication, n (%)§ | 578 (30.5) | 181 (28.1) | 759 (29.9) |
| Use of ACE inhibitors | 147 (7.8) | 57 (8.9) | 204 (8.0) |
| Use of ARBs | 289 (15.2) | 89 (13.8) | 378 (14.9) |
| Use of calcium channel blockers | 25 (1.3) | 4 (0.6) | 29 (1.1) |
| Use of diuretics | 39 (2.1) | 11 (1.7) | 50 (2.0) |
*Plus-minus values are mean±SD except where noted.
†Race or ethnic group was reported by participants.
‡Data are geometric mean (coefficient of variation, %).
§Assessed through a review of medical history.
¶eGFR denotes the estimated glomerular filtration rate calculated with the use of the serum creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N, number of randomised patients; n, number.